Brief: Longeveron Announces Positive Top-Line Results For Lomecel-B™ In Its Phase 2A Clinical Trial for Mild Alzheimer’S Treatment

Longeveron

05/10/2023 12:14

Oct 5 (Reuters) - Longeveron Inc  LGVN.O :
    * LONGEVERON ANNOUNCES POSITIVE TOP-LINE RESULTS FOR
LOMECEL-B™ IN
ITS CLEAR MIND PHASE 2A CLINICAL TRIAL IN THE TREATMENT OF MILD
ALZHEIMER’S DISEASE
    * LONGEVERON INC - PRIMARY ENDPOINT OF SAFETY MET ACROSS ALL
STUDY
GROUPS
    * LONGEVERON INC - OTHER DOSES DEMONSTRATED NUMERICAL
SLOWING/PREVENTION OF DISEASE WORSENING RELATIVE TO PLACEBO
    * LONGEVERON INC - ADDITIONAL BIOMARKER DATA EXPECTED TO BE
ANNOUNCED IN COMING WEEKS
    * LONGEVERON INC - STATISTICAL SIGNIFICANCE MET FOR
SECONDARY
ENDPOINT

Source text for Eikon:  ID:nGNX8KPBmL 
Further company coverage:  LGVN.O 

 ((Reuters.Briefs@thomsonreuters.com))